![]() |
市場調查報告書
商品編碼
1417592
全球眼科黏彈性器材市場評估:依產品類型、成分、應用、最終用戶、地區、機會、預測(2017-2031)Ophthalmic Viscoelastic Devices Market Assessment, By Product Type, By Composition, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F |
全球眼科黏彈性器材市場規模預計到2023年將達到30.1億美元,到2031年將達到44.8億美元,2023-2031年預測期間複合年增長率為5.1%。由於眼科疾病盛行率的增加、老年人口的增加以及眼科設備的進步等主要因素,全球眼科黏彈性設備市場正在呈現顯著成長。此外,生活方式的改變、螢幕時間的增加以及慢性病盛行率的上升導致眼部疾病患者數量的增加,從而推動了對眼科黏彈性裝置的需求。
由於白內障、青光眼、角膜移植和玻璃體視網膜手術等各種手術的需求不斷增加,預計眼科黏彈性裝置市場將顯著成長。老年人群特別容易出現視力障礙,進一步增加了對眼科黏彈性裝置的需求。此外,糖尿病、高血壓等慢性病的流行也對市場產生影響,而這些疾病往往伴隨眼部疾病。技術進步、支持醫療基礎設施的政府政策以及醫療設備的可用性正在推動市場成長。然而,手術後眼壓升高的風險以及替代療法的存在等問題可能會阻礙市場擴張。
2023年4月,Bausch + Lomb Corporation宣佈在美國市場推出兩款黏彈性裝置:StableVisc cohesive OVD和TotalVisc Viscoelastic System。這兩種裝置均含有透明質酸鈉和山梨醇的混合物,與其他可用的眼科黏彈性裝置相比,可提供強大的物理屏障並增強自由基清除能力。
屈光不正、白內障、糖尿病性視網膜病變、青光眼和老年黃斑部病變(AMD)等眼科疾病的盛行率日益增加,對全球眼科黏彈性裝置(OVD)市場產生了重大影響。由於不健康的生活方式、營養不良和螢幕時間過長等因素,這些疾病呈現上升趨勢。這些疾病的日益普及預計將推動對廣泛用於眼科手術的眼科黏彈性裝置的需求。根據世界衛生組織 2023 年 8 月的情況說明書,全球有 22 億人患有近視或遠視。其中,10億人因遠視力障礙而失明,其中9,400萬人因白內障、8,840萬人因屈光不正、800萬人因老年黃斑部病變、770萬人因青光眼和390萬人因糖尿病視網膜病變而失明。老花眼影響 8.26 億人,是損害近距離視力的主要疾病。
人口老化是導致眼科黏彈性裝置需求不斷增長的另一個重要面向。老年人更有可能患有影響眼睛的慢性疾病和眼科疾病。據世界衛生組織稱,到2030年,世界上六分之一的人將超過60歲。60歲以上人口將從2020年的10億增加到2030年的14億。到2050年,地球上60歲以上的人口數量將翻倍,達到21億人。預計到 2050 年,80 歲及以上的人口數量將翻兩番,達到 4.26 億。
預計在預測期內,黏性眼科黏彈性裝置領域將在全球眼科黏彈性裝置中佔據主導地位。黏性眼科黏彈性裝置被廣泛使用,因為它們具有高黏度(增加手術環境穩定性)和高黏性(有利於手術切除)等優點。這可以穩定結構並允許對其佔據的空間加壓。白內障盛行率的增加和眼科黏彈性裝置的技術進步是黏性眼科黏彈性裝置領域佔據主導地位的原因。市場公司正在擴大其產品組合,以獲得該產品類別的競爭優勢。
本報告研究分析了全球眼科黏彈性器材市場,提供市場規模和預測、市場動態、主要參與者現狀和前景等。
Global ophthalmic viscoelastic devices market size was valued at USD 3.01 billion in 2023 and is expected to reach USD 4.48 billion in 2031, with a CAGR of 5.1% for the forecast period between 2023 and 2031F. The global market for ophthalmic viscoelastic devices is experiencing significant growth due to several key factors, such as the increasing prevalence of eye-related disorders, the growing elderly population, and advancements in ophthalmic devices. Additionally, lifestyle changes, prolonged screen time, and the rising incidence of chronic diseases contribute to more patients with eye disorders, driving the demand for ophthalmic viscoelastic devices.
The ophthalmic viscoelastic devices market is projected to grow substantially, driven by the increasing demand for various surgical procedures, including those related to cataracts, glaucoma, corneal transplantation, and vitreoretinal surgery. The geriatric population is particularly susceptible to vision impairment, further boosting the need for ophthalmic viscoelastic devices. Furthermore, the market is influenced by the prevalence of chronic conditions such as diabetes and hypertension, which are often associated with eye disorders. Technological advancements, government policies supporting healthcare infrastructure, and enhanced availability of medical devices are fueling the market growth. However, challenges such as the risk of a rise in ocular pressure after surgery and the presence of alternative therapies may impede market expansion.
In April 2023, Bausch + Lomb Corporation announced the launch of two viscoelastic devices, StableVisc cohesive ophthalmic viscosurgical device (OVD) and TotalVisc Viscoelastic System, in the United States market. Both the devices contain a mix of sodium hyaluronate and sorbitol, providing a strong physical barrier and delivering increased free radical scavenging capabilities compared to other available ophthalmic viscoelastic devices.
The increasing prevalence of ophthalmic disorders, such as refractive errors, cataracts, diabetic retinopathy, glaucoma, and age-related macular degeneration (AMD), significantly impacts the global ophthalmic viscoelastic devices (OVDs) market. These disorders are on the rise due to factors like unhealthy lifestyles, nutritional deficiency, and longer screen time. The increasing prevalence of these diseases is expected to drive the demand for ophthalmic viscoelastic devices, as these devices are extensively used in ophthalmic surgeries. A WHO factsheet from August 2023 states that 2.2 billion people worldwide suffer from near or far-sightedness. Out of which, 1 billion are affected by blindness from distance vision impairment, including 94 million people with cataracts, 88.4 million with refractive error, 8 million with age-related macular degeneration, 7.7 million with glaucoma, and 3.9 million with diabetic retinopathy. Presbyopia, which affects 826 million people, is the main condition that impairs close vision.
Another important aspect that has contributed significantly to the increased need for ophthalmic viscoelastic devices is the aging population. People who are older tend to have comorbid ailments such as chronic illnesses and ophthalmic disorders that affect their eyes. As per WHO, by 2030, one in six people in the world will be 60 years of age or older. By 2030, there will be 1.4 billion over-60s, compared to 1 billion in 2020. By 2050, there will be twice as many people 60 years or older on the planet, i.e., 2.1 billion people. It is projected that the population of 80 years of age or older will quadruple to 426 million by 2050.
The cohesive ophthalmic viscoelastic devices segment in global ophthalmic viscoelastic devices is expected to dominate during the forecast period. Cohesive ophthalmic viscoelastic devices are being used extensively as they offer advantages such as high viscosity, which increases the stability of the surgical environment, and high cohesion, which eases surgical removal. It stabilizes structures and enables pressurization of the space they occupy. The growing prevalence of cataracts and technological advancements in ophthalmic viscoelastic devices are reasons for the dominance of the cohesive ophthalmic viscoelastic devices segment. Market players are expanding their product portfolio to gain a competitive edge in this product category.
With high investment in research and development activities, technological advancements by key players, and advanced healthcare infrastructure in countries, like the United States and Canada, the region is expected to dominate the market with the highest value share. Supportive government initiatives for managing the growing number of ophthalmic surgeries are embracing the growth of the market in the region. High disposable income and preference for ophthalmic treatments of eye problems, along with the presence of key players, are contributing to the dominance of North America in the ophthalmic viscoelastic devices market.
Growth in healthcare infrastructure in developing countries and efforts to reduce the burden of ophthalmic disorders like integrated people-centered eye care (IPEC) by WHO is expected to set a positive trend for the market. Key market players focus on developing innovative products and expanding their market presence. In terms of regional growth, Asia-Pacific market is expected to experience a robust CAGR, driven by its sizable population, rising disposable income, and growing patient awareness of the need for eye care. In the future, surgeons might be able to carry out more intricate and accurate surgeries, and viscoelastic devices might be utilized to operate a wider range of ocular ailments.
The global ophthalmic viscoelastic devices market consists of market players like Bausch & Lomb Incorporated, Alcon Laboratories, Inc., Johnson & Johnson Surgical Vision Inc., and others, who are expanding their product offerings and giving their customers access to a wide range of cutting-edge and novel products.
For instance, In January 2022, Glaukos Corporation announced that it received 510(k) clearance from the United States Food and Drug Administration (FDA) for its viscoelastic device named 'iPRIME Viscodelivery System'. Glaukos is an ophthalmic medtech and pharmaceutical company dedicated to developing novel therapies for managing glaucoma, retinal diseases, and corneal disorders. iPRIME Viscodelivery System is a single-use, sterile, minimally-invasive device for delivering viscoelastic fluid during ophthalmic surgeries.
All segments will be provided for all regions and countries covered:
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.